Bafna Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 5, 2025, 10:55 am

Competitors of Bafna Pharmaceuticals Ltd

All Competitor Stocks of Bafna Pharmaceuticals Ltd

Quarterly Result

Last Updated: February 28, 2025, 8:32 pm

Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

• For Sales, as of Dec 2024, the value is 33.19 Cr.. The value appears to be declining and may need further review. It has decreased from 40.32 Cr. (Sep 2024) to 33.19 Cr., marking a decrease of 7.13 Cr..
• For Expenses, as of Dec 2024, the value is 30.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 36.53 Cr. (Sep 2024) to 30.13 Cr., marking a decrease of 6.40 Cr..
• For Operating Profit, as of Dec 2024, the value is 3.06 Cr.. The value appears to be declining and may need further review. It has decreased from 3.79 Cr. (Sep 2024) to 3.06 Cr., marking a decrease of 0.73 Cr..
• For OPM %, as of Dec 2024, the value is 9.22%. The value appears to be declining and may need further review. It has decreased from 9.40% (Sep 2024) to 9.22%, marking a decrease of 0.18%.
• For Other Income, as of Dec 2024, the value is 0.18 Cr.. The value appears to be declining and may need further review. It has decreased from 1.02 Cr. (Sep 2024) to 0.18 Cr., marking a decrease of 0.84 Cr..
• For Interest, as of Dec 2024, the value is 0.64 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.62 Cr. (Sep 2024) to 0.64 Cr., marking an increase of 0.02 Cr..
• For Depreciation, as of Dec 2024, the value is 1.66 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.58 Cr. (Sep 2024) to 1.66 Cr., marking an increase of 0.08 Cr..
• For Profit before tax, as of Dec 2024, the value is 0.94 Cr.. The value appears to be declining and may need further review. It has decreased from 2.61 Cr. (Sep 2024) to 0.94 Cr., marking a decrease of 1.67 Cr..
• For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
• For Net Profit, as of Dec 2024, the value is 0.95 Cr.. The value appears to be declining and may need further review. It has decreased from 2.62 Cr. (Sep 2024) to 0.95 Cr., marking a decrease of 1.67 Cr..
• For EPS in Rs, as of Dec 2024, the value is 0.40. The value appears to be declining and may need further review. It has decreased from 1.11 (Sep 2024) to 0.40, marking a decrease of 0.71.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: March 7, 2025, 9:08 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: March 14, 2025, 4:03 pm

Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2024, the value is ₹24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 24.00 Cr..
• For Reserves, as of Sep 2024, the value is ₹59.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to ₹59.00 Cr., marking an increase of 2.00 Cr..
• For Borrowings, as of Sep 2024, the value is ₹19.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 24.00 Cr. (Mar 2024) to ₹19.00 Cr., marking a decrease of 5.00 Cr..
• For Other Liabilities, as of Sep 2024, the value is ₹33.00 Cr.. The value appears to be improving (decreasing). It has decreased from 42.00 Cr. (Mar 2024) to ₹33.00 Cr., marking a decrease of 9.00 Cr..
• For Total Liabilities, as of Sep 2024, the value is ₹134.00 Cr.. The value appears to be improving (decreasing). It has decreased from 148.00 Cr. (Mar 2024) to ₹134.00 Cr., marking a decrease of 14.00 Cr..
• For Fixed Assets, as of Sep 2024, the value is ₹56.00 Cr.. The value appears strong and on an upward trend. It has increased from 40.00 Cr. (Mar 2024) to ₹56.00 Cr., marking an increase of 16.00 Cr..
• For CWIP, as of Sep 2024, the value is ₹2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 12.00 Cr. (Mar 2024) to ₹2.00 Cr., marking a decrease of 10.00 Cr..
• For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Sep 2024, the value is ₹77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 95.00 Cr. (Mar 2024) to ₹77.00 Cr., marking a decrease of 18.00 Cr..
• For Total Assets, as of Sep 2024, the value is ₹134.00 Cr.. The value appears to be declining and may need further review. It has decreased from 148.00 Cr. (Mar 2024) to ₹134.00 Cr., marking a decrease of 14.00 Cr..

Notably, the Reserves (59.00 Cr.) exceed the Borrowings (19.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
• For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
• For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
• For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
• For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
• For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
• For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
• For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
• For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
• For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
• For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
• For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
• For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
• For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
• For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
• For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
• For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
• For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
• For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
• For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
• For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
• For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
• For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
• For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
• For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
• For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
• For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
• For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
• For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
• For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
• For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness